Omeros (OMER) Given a $32.00 Price Target by Maxim Group Analysts

Omeros (NASDAQ:OMER) has been assigned a $32.00 price target by analysts at Maxim Group in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 128.25% from the company’s current price.

Several other research analysts also recently commented on the company. BidaskClub upgraded Omeros from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, August 29th. HC Wainwright set a $34.00 target price on Omeros and gave the stock a “buy” rating in a research note on Wednesday, August 29th. Finally, ValuEngine upgraded Omeros from a “buy” rating to a “strong-buy” rating in a research note on Monday, September 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $27.56.

Shares of OMER opened at $14.02 on Thursday. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.00. The stock has a market capitalization of $699.85 million, a P/E ratio of -17.75 and a beta of 3.90.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The company had revenue of $4.61 million during the quarter, compared to the consensus estimate of $3.07 million. During the same period in the prior year, the business posted ($0.16) earnings per share. As a group, analysts forecast that Omeros will post -2.53 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its stake in Omeros by 10.2% in the 1st quarter. Principal Financial Group Inc. now owns 29,433 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 2,723 shares during the period. Rhumbline Advisers boosted its position in shares of Omeros by 7.2% during the 2nd quarter. Rhumbline Advisers now owns 44,746 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 3,021 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in shares of Omeros by 1.8% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 244,374 shares of the biopharmaceutical company’s stock valued at $5,965,000 after acquiring an additional 4,260 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Omeros by 24.7% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 23,700 shares of the biopharmaceutical company’s stock valued at $579,000 after acquiring an additional 4,700 shares during the last quarter. Finally, First Interstate Bank boosted its position in shares of Omeros by 100.0% during the 3rd quarter. First Interstate Bank now owns 10,000 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 47.50% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: What are no-load funds?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply